Compare KFY & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFY | TLX |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | 1998 | N/A |
| Metric | KFY | TLX |
|---|---|---|
| Price | $81.17 | $9.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $73.00 | $21.13 |
| AVG Volume (30 Days) | ★ 504.8K | 146.0K |
| Earning Date | 06-17-2026 | 08-19-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 13.48 | N/A |
| EPS | ★ 5.22 | N/A |
| Revenue | ★ $1,819,519,000.00 | N/A |
| Revenue This Year | $6.92 | N/A |
| Revenue Next Year | $3.25 | N/A |
| P/E Ratio | ★ $14.99 | $150.33 |
| Revenue Growth | ★ 12.20 | N/A |
| 52 Week Low | $58.27 | $6.28 |
| 52 Week High | $79.97 | $14.27 |
| Indicator | KFY | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 70.01 | 40.21 |
| Support Level | $66.27 | $9.37 |
| Resistance Level | N/A | $11.38 |
| Average True Range (ATR) | 1.86 | 0.27 |
| MACD | 0.49 | -0.18 |
| Stochastic Oscillator | 98.53 | 1.28 |
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.